Forum Agenda

July 23, 10:00-12:10

Advanced Stem Cell Culture Technology Session

Stay tuned

Planners
Shang Xiao: Founder and Chairman of Youyi Bio
Wei Wu: General Manager of Youyi Bio

 

10:00-10:05 Opening Remarks
Shang Xiao: Founder and Chairman of Youyi Bio

 

10:05-10:20 Culture of MSC: from 2D to 3D, and beyond
Lianming Liao: Chief Scientific Officer (CSO) of Topcel Bio

 

10:20-10:35 High-Efficiency Exosome Production Factory Driven by All-Factor Integrated Medium
Ali Mohsin: Vice President of R&D, Youyi Bio

 

10:35-10:50 Application of Domestic CUR Bioreactor in the CGT Field
Chaodong Li: Chief Scientist of JYSS Bio

 

10:50-11:30 Panel Discussion: Supply Chain Risks and Challenges in Cell Therapy Under Dual-Track Regulation Following the Implementation of Orders 818 and 828
Ting Zhang (Moderator): CEO of Regend Therapeutics
Yutian Shen: Co-founder and CEO of Cellgenes
Zhiying He: Professor and Executive Director of the Institute for Regenerative Medicine, East Hospital Affiliated to Tongji University
Yonghong Yin: Deputy General Manager of Celliver Bio
Yijie Yang: Co-founder and CEO of HUIXIN LIFETECH
Yueming Wang: Former General Manager of AegleStem® Therapeutic; International Advisor to the Beijing Daxing International Airport Lin-gang Economic Zone

 

11:30-12:10 Panel Discussion: Compliance and Prospects of MSC (Mesenchymal Stem Cell) Therapy
Wei Wu (Moderator): General Manager of Youyi Bio
Guanghua Yang: Chief Scientist, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; Chairman of NucleusGene (Shanghai) Pharmaceutical Technology Co., Ltd.
Wenjun Zhang: Deputy Director, Institute of Hematology, Tongji University; Deputy Director, Cancer Center, Tongji Hospital; Deputy Director, Institute of Hematology, Tongji University School of Medicine
Chencai Liu: Deputy General Manager of Qichuang Research Institute
Ruiting Pan: Managing Director and Head of China, JIF Capital